Loading stock…

Aier Eye Hospital Group Co., Ltd. (300015) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Aier Eye Hospital Group Co., Ltd.

300015Market cap $11BPrice $1.2

Country🇨🇳China

SectorHealthcare

IndustryHealthcare Services

Runs the world's largest network of eye hospitals, treating everything from cataracts to myopia across China and beyond. Founded in 2003, it's grown to over 800 hospitals, betting big on China's aging population needing better vision care.

In Bastion Portfolios?

52W Return-32%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+11%6

Rev CAGR (3y)+9%6

Rev CAGR (5y)+28%10

Earnings Forecast

EPS Growth Y+1+4%5

EPS Growth Y+2+26%8

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin21%8

Net Income Margin11%6

Free Cash Flow Margin16%7

Debt

Net Debt/EBITDA0.19

Efficiency

ROE11%5

ROA8%8

Earnings Stability77

GEAR+VERY STRONG92

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)1091

P/E Ratio (Forward 3y)164

P/BV3.25

EV Multiples

EV/EBITDA Fwd115

EV/EBIT Fwd146

Yield

Free Cash Flow Yield5.0%6

Dividend Yield2.0%5

Momentum

Short term

1 month return-4%6

3 month return-2%6

YTD return-26%2

Mid term

Price vs 52wHigh63%2

1 year return-34%1

Long term

3 year return-54%1

5 year return-73%1

Risk Shield

Price Risk

Beta0.39

Volatility28%8

Free Cash Flow

Free Cash Flow Margin16%7

Free Cash Flow Yield5.0%6

Quality

ROCE17%8

Earnings Stability77

Net Debt/EBITDA0.19

02Growth

Is it actually growing, and how fast?

300015Aier Eye Hospital Group Co.

Revenue FY25$3.2B

GROWTH RATING↗

STRONG70 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+28%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+4%5

EPS growth, FY27E+26%8

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 70% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 28%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 9%/yr), so margins should widen.

WATCH

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A top-tier grower.

03Price Momentum

Is the market behind it right now?

300015Aier Eye Hospital Group Co.

Total return Current147%

Price return Current130%

MOMENTUM RATING↗

VERY WEAK13 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-2%6

YTD return-26%2

MID & LONG-TERM▾SCORE

% of 52-week high63%2

1-year return-34%1

3-year return-54%1

5-year return-73%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-54% over three years and -73% over five), behind 90% of the market.

It's down 34% over the past year, now 37% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-26%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Aier Eye. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

300015Aier Eye Hospital Group Co.

Revenue FY25$3.2B

GROWTH RATING↗

STRONG70 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+28%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+4%5

EPS growth, FY27E+26%8

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 70% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 28%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 9%/yr), so margins should widen.

WATCH

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A top-tier grower.

03Price Momentum

Is the market behind it right now?

300015Aier Eye Hospital Group Co.

Total return Current147%

Price return Current130%

MOMENTUM RATING↗

VERY WEAK13 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-2%6

YTD return-26%2

MID & LONG-TERM▾SCORE

% of 52-week high63%2

1-year return-34%1

3-year return-54%1

5-year return-73%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-54% over three years and -73% over five), behind 90% of the market.

It's down 34% over the past year, now 37% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-26%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Aier Eye. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community